Dublin, April 01, 2026 (GLOBE NEWSWIRE) — The “Outpatient Oncology Infusion Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The outpatient oncology infusion market is experiencing significant growth, projected to increase from $14.02 billion in 2025 to $15.12 billion in 2026, at a CAGR of 7.8%. This growth is driven by rising cancer prevalence, enhanced outpatient oncology infrastructure, adoption of infusion therapies, improved survival rates requiring ongoing care, and availability of advanced infusion devices.
Looking ahead, the market is anticipated to reach $20.21 billion by 2030, maintaining a CAGR of 7.5%. Factors contributing to this upward trend include increased demand for precision oncology treatments, investments in outpatient infusion centers, expansion of home-compatible technologies, and emphasis on cost-efficient cancer care. Major trends include a shift toward outpatient treatment models, adoption of targeted therapies, use of smart infusion pumps, and expansion of ambulatory infusion centers.
The rise in cancer cases, largely attributed to aging populations, underscores the need for outpatient oncology infusion, allowing patients to receive chemotherapy, immunotherapy, or targeted therapy without hospital admission. For instance, Macmillan Cancer Support projects the number of individuals living with cancer in the UK to exceed 3 million, reaching 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040.
Innovation is at the forefront, with companies like Baxter International Inc. advancing infusion systems to enhance safety and treatment delivery. Baxter’s U.S. FDA-cleared Novum IQ large-volume infusion pump exemplifies this, offering precise infusions with embedded safety features, suitable for outpatient oncology centers and hospitals alike. In another strategic move, Cardinal Health acquired Integrated Oncology Network in December 2024, aiming to broaden its oncology network and enhance value-based care delivery.
Leading companies, including Medtronic plc, Becton Dickinson and Company, and Fresenius Kabi AG, are key players in this market, with North America being the largest region in 2025. However, Asia-Pacific is anticipated to be the fastest-growing region during the forecast period.
Key Reasons to Purchase:
- Gain global insights with an exhaustive analysis covering 16 geographies, providing a unique worldwide perspective.
- Evaluate the influence of macroeconomic factors like geopolitical tensions, trade policies, inflation, and evolving regulations on the market.
- Formulate regional and national strategies using localized data and insights.
- Identify high-growth sectors for strategic investment.
- Leverage forecast data to outperform competitors and understand market-driving trends.
- Achieve a customer-centric approach via end-user analysis.
- Benchmark against key competitors concerning market share, innovation, and brand strength.
- Assess market potential with total addressable market and attractiveness scoring.
- Support internal and external presentations with credible and high-quality data and analysis.
- Receive timely updates and analytics in convenient Excel formats for easy data extraction.
Market Segmentation and Competitive Landscape:
- Products: Infusion Pumps, Intravenous Sets, Intravenous Cannulas, Needleless Connectors
- Therapies: Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy
- Applications: Lung Cancer, Liver Cancer, Breast Cancer, Prostate Cancer, Other Cancers
- End-Users: Hospitals, Outpatient Clinics, Home Care Settings
Company analysis covers leading firms such as Medtronic plc, Becton Dickinson, Baxter International, and others. It evaluates their market positioning, financials, and innovative capacities. The company scoring matrix ranks enterprises based on quantitative metrics such as market share, product innovation, and brand strength.
Geographic and Time Coverage
The report spans major regions including Asia-Pacific, Western and Eastern Europe, North America, and others. It also provides both historical data and a ten-year forecast, supported by industry-specific ratios and GDP correlations.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $15.12 Billion |
| Forecasted Market Value (USD) by 2030 | $20.21 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Global |
The companies featured in this Outpatient Oncology Infusion market report include:
- Medtronic plc
- Becton Dickinson and Company
- Baxter International Inc.
- Fresenius Kabi AG
- Terumo Corporation
- Nipro Corporation
- Smiths Medical Inc.
- ICU Medical Inc.
- B. Braun Melsungen AG
- InfuSystem Holdings Inc.
- BPL Medical Technologies Private Limited
- Angiplast Private Limited
- Bio-Med Healthcare Products Private Limited
- Lars Medicare Private Limited
- Micrel Medical Devices S.A.
- AKAS Infusions Private Limited
- Mais India Medical Devices Private Limited
- Wellead Medical Co. Ltd.
- AdvaCare Pharma USA LLC
- Polymed Medical Devices Private Limited
For more information about this report visit https://www.researchandmarkets.com/r/osracr
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Outpatient Oncology Infusion Market
